Exelixis Announces Positive Results from Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma
- The results will be Presented at ASCO 2016 Genitourinary Cancers Symposium this month.
- Data further highlight clinical benefit of cabozantinib across subgroups of patients with advanced renal cell carcinoma
- METEOR data are the foundation for the U.S. NDA filing submitted last month, EU filing planned for early 2016
Exelixis (EXEL) presented data from subgroup analyses of METEOR, the phase 3 pivotal trial . . .
This content is for paid subscribers.
Today’s Highlights January 5, 2016